Pharvaris Past Earnings Performance
Past criteria checks 0/6
Pharvaris's earnings have been declining at an average annual rate of -42.9%, while the Pharmaceuticals industry saw earnings growing at 1.7% annually.
Key information
-42.9%
Earnings growth rate
-0.07%
EPS growth rate
| Pharmaceuticals Industry Growth | 6.0% |
| Revenue growth rate | n/a |
| Return on equity | -26.3% |
| Net Margin | n/a |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
No updates
Recent updates
Pharvaris: Digging Deep For Sufficient Market Size
Jan 17We Think Pharvaris (NASDAQ:PHVS) Can Afford To Drive Business Growth
Oct 09
Pharvaris (NASDAQ:PHVS) Is In A Good Position To Deliver On Growth Plans
May 13Companies Like Pharvaris (NASDAQ:PHVS) Are In A Position To Invest In Growth
Jan 11We Think Pharvaris (NASDAQ:PHVS) Can Afford To Drive Business Growth
Sep 26Pharvaris GAAP EPS of -€0.38
Sep 12Pharvaris slips 19% after FDA clinical hold on hereditary angioedema candidate
Aug 22We're Not Very Worried About Pharvaris' (NASDAQ:PHVS) Cash Burn Rate
Jun 08Pharvaris (NASDAQ:PHVS) Is In A Good Position To Deliver On Growth Plans
Dec 21We're Not Very Worried About Pharvaris' (NASDAQ:PHVS) Cash Burn Rate
Aug 25Pharvaris reports Q1 results
May 26Revenue & Expenses BreakdownBeta
How Pharvaris makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 0 | -101 | 31 | 66 |
| 30 Sep 23 | 0 | -107 | 30 | 63 |
| 30 Jun 23 | 0 | -92 | 31 | 59 |
| 31 Mar 23 | 0 | -83 | 31 | 58 |
| 31 Dec 22 | 0 | -76 | 29 | 57 |
| 30 Sep 22 | 0 | -49 | 27 | 52 |
| 30 Jun 22 | 0 | -50 | 23 | 47 |
| 31 Mar 22 | 0 | -53 | 20 | 41 |
| 31 Dec 21 | 0 | -43 | 18 | 36 |
| 30 Sep 21 | 0 | -41 | 15 | 33 |
| 30 Jun 21 | 0 | -38 | 12 | 29 |
| 31 Mar 21 | 0 | -29 | 8 | 25 |
| 31 Dec 20 | 0 | -26 | 5 | 20 |
| 30 Sep 20 | 0 | -19 | 4 | 14 |
| 31 Dec 19 | 0 | -8 | 2 | 6 |
Quality Earnings: PHVS is currently unprofitable.
Growing Profit Margin: PHVS is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: PHVS is unprofitable, and losses have increased over the past 5 years at a rate of 42.9% per year.
Accelerating Growth: Unable to compare PHVS's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: PHVS is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-6.8%).
Return on Equity
High ROE: PHVS has a negative Return on Equity (-26.27%), as it is currently unprofitable.